Results 91 to 100 of about 5,633 (190)

Experience with febuxostat in a patient with severe disabling gout

, 2017
Gout is a chronic disease that frequently leads to disability if urate-lowering therapy is inefficient. The paper presents the positive experience with febuxostat, a novel non-purine xanthine oxidase inhibitor, in a young patient with disabling chronic ...
R. U. Shayakhmetova, M. S. Eliseev
core   +1 more source

The mass spectrometry (MS) parameters for assays of febuxostat.

, 2016
The mass spectrometry (MS) parameters for assays of febuxostat.
Zhu Luo (1525882), Mei Li (217363), Maozhi Liang (3180312), Feng Nan (3180315), Jia Miao (3180309), Zhihui Chen (89636)   +5 more
core   +1 more source

The Roles of ROS Generation in RANKL-Induced Osteoclastogenesis : Suppressive Effects of Febuxostat [PDF]

, 2020
Receptor activator of NF-κB ligand (RANKL), a critical mediator of osteoclastogenesis, is upregulated in multiple myeloma (MM). The xanthine oxidase inhibitor febuxostat, clinically used for prevention of tumor lysis syndrome, has been demonstrated to ...
ヒアサ, マサヒロ, テラマチ, ジュンペイ, 174880/profile-ja.html, 賀川, 久美子, Fujii, Shiroh, 谷本, 幸多朗, 230, Hiasa, Masahiro, Oura, Masahiro, 876, Ashtar, Mohannad, タカハシ, マミコ, 919, 10511321, アベ, マサヒロ, Teramachi, Jumpei, 1591, Matsumoto, Toshio, シミズ, ソウ, 528, Higa, Yoshiki, 189914/profile-ja.html, 遠藤, 逸朗, 00618473, Harada, Takeshi, Udaka, Kengo, 三木, 浩和, 1634, 80263812, 349366/profile-ja.html, テンシン, ヒロフミ, 田中, 栄二, Endo, Itsuro, 145663/profile-ja.html, 20157374, 藤井, 志朗, 10432759, Tenshin, Hirofumi, 208060/profile-ja.html, 中村, 信元, Sogabe, Kimiko, Nakamura, Shingen, 384, フジイ, シロウ, 住谷, 龍平, Kagawa, Kumiko, ハラダ, タケシ, Miki, Hirokazu, 364652/profile-ja.html, 174876/profile-ja.html, 原田, 武志, 281316/profile-ja.html, 323782/profile-ja.html, カガワ, クミコ, Tanaka, Eiji, エンドウ, イツロウ, スミタニ, リョウヘイ, 寺町, 順平, Tanimoto, Kotaro, 950, 安倍, 正博, 日浅, 雅博, 20515986, ヒガ, ヨシキ, 60265/profile-ja.html, ミキ, ヒロカズ, 40273693, マツモト, トシオ, 松本, 俊夫, タニモト, コウタロウ, オオウラ, マサヒロ, 323, 326, 723, 曽我部, 公子, 60162/profile-ja.html, 1164, Shimizu, So, 450, Abe, Masahiro, 337582/profile-ja.html, Sumitani, Ryohei, Oda, Asuka, ソガベ, キミコ, Takahashi, Mamiko, オダ, アスカ, 246784/profile-ja.html, 清水, 宗, 大浦, 雅博, 天眞, 寛文, 580, 90511337, 229265/profile-ja.html, アシテル, モハナッド, ナカムラ, シンゲン, 50511333, ウダカ, ケンゴ, タナカ, エイジ, Bat-Erdene, Ariunzaya   +98 more
core  

COMPARISON BETWEEN RENOPROTECTIVE EFFECTS OF FEBUXOSTAT AND ALLOPURINOL IN CHRONIC KIDNEY DISEASE PATIENTS WITH HYPERURICEMIA

, 2023
Objective: The objective of the study was to compare the renoprotective effects of febuxostat versus allopurinol in chronic kidney disease patients with hyperuricemia.
matta, saksham, Bhutani, Garima, rani, seema, Saini, Rahul, Arora, Tarun, Garg, Renu   +5 more
core  

The place of febuxostat in the treatment of gout

, 2020
The curation of patients with gout involves the mandatory prescription of pathogenetic therapy with urate-lowering drugs, among which xanthine oxidase inhibitors, such as allopurinol and febuxostat, are most widely used. According to various national and
A. M. Novikova, M. S. Eliseev
core   +1 more source

Febuxostat efficiently reduces the progression of chronic kidney disease in asymptomatic hyperuricemia: an interventional study

The Egyptian Journal of Internal Medicine
Background Therapeutic approaches for addressing asymptomatic chronic kidney disease (CKD) with renal impairment requires careful consideration, as there is a lack of substantial evidence endorsing specific medications.
Showkat Azad, Pradip Kumar Dutta, Md Nurul Huda, Mohammad Abdul Kader, Biplob Kumar Barua, Mohammad Shawkat Ali, Maria Mehjabin Akhi, Mishu Rahman, Jannatul Efte Ekra, Md. Sujan Islam, Sadia Afrin, Mohammed Mehadi Hassan Chowdhury, Subodh Kumar Sarkar, Ashekul Islam   +13 more
doaj   +1 more source

Comparative efficacy and safety of febuxostat and allopurinol in chronic kidney disease stage 3–5 patients with asymptomatic hyperuricemia: a network meta-analysis

Renal Failure
Objective This study evaluates and compares the effectiveness and safety of febuxostat and allopurinol in chronic kidney disease (CKD) stages 3–5 patients with asymptomatic hyperuricemia using a network meta-analysis.Methods A systematic review and ...
Jiaojiao Chen, Yanyun Zhang, Yinglin Wang, Lu Chen   +3 more
doaj   +1 more source

Crystal structure of febuxostat–acetic acid (1/1)

, 2015
The asymmetric unit of the title compound [systematic name: 2-(3-cyano-4-isobutyloxyphenyl)-4-methylthiazole-5-carboxylic acid–acetic acid (1/1)], C16H16N2O3S·CH3COOH, contains a febuxostat molecule and an acetic acid molecule. In the febuxostat molecule,
Xiu-Rong Hu, Min Wu, Jian-Ming Gu, Gu-Ping Tang   +3 more
core   +1 more source

Xanthine oxidoreductase inhibition ameliorates high glucose-induced glomerular endothelial injury by activating AMPK through the purine salvage pathway

Scientific Reports
Xanthine oxidoreductase (XOR) contributes to reactive oxygen species production. We investigated the cytoprotective mechanisms of XOR inhibition against high glucose (HG)-induced glomerular endothelial injury, which involves activation of the AMP ...
Keum-Jin Yang, Hwajin Park, Yoon-Kyung Chang, Cheol Whee Park, Suk Young Kim, Yu Ah Hong   +5 more
doaj   +1 more source

Allopurinol to Febuxostat: How far have we come?

, 2010
For decades allopurinol has been used as a xanthine oxidase inhibitor for treatment of hyperuricemia and gout. Although effective in many patients, some experience sensitivity to the drug.
Melissa Stechschulte, Amy L. Stockert
core   +1 more source